Fig. 7
From: Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
The effect of ERK inhibitor U0126 on post-reperfusion arrhythmia characteristics and mortality. (A) Quantification of the incidence of cardiac arrhythmia characteristics and mortality during post-ischemia reperfusion in rats with myocardial I/R injury. Numbers of animals per category are indicated in parentheses. CON, control; Em, empagliflozin; VT, ventricular tachycardia; First episode of VT, showing the first run of VT; AVB, AV block; PVT, polymorphic VT, VF, ventricular fibrillation, Sinus, rat in sinus rhythm. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Em. Each group included 10–15 rats. Values for control and rats with empagliflozin are repeated from Table 1 for comparison. (B) Mean VT durations in the four study group. Rats without VT were indicated as 0 s duration. Each group included 10–15 rats. Values for control and rats with empagliflozin are repeated from Fig. 4 for comparison. (C) The longest episode of VT duration (LVT) in the four study group. Rats without VT were indicated as 0 s duration. Each group included 10–15 rats. Values for control and rats with empagliflozin are repeated from Fig. 4 for comparison. (D) The onset time of first VT episode after cardiac reperfusion in the four study group. Each group included 10–15 rats. Values for control and rats with empagliflozin are repeated from Fig. 4 for comparison